

**Supplementary Table 1.** Prespecified subgroup analysis of the effect of estrogen plus progestin (E+P) on nonmelanoma skin cancer, stratified by characteristics at baseline\*

Subgroup	E+P		Placebo		HR (95% CI)	P
	No. of events	Annualized %	No. of events	Annualized %		
Overall	494	1.05	486	1.11	0.95 (0.83 to 1.07)	
Age, y						.138
50–59	108	0.65	104	0.67	0.96 (0.73 to 1.26)	
60–69	246	1.18	217	1.11	1.06 (0.88 to 1.27)	
70–79	140	1.49	165	1.84	0.79 (0.63 to 0.99)	
Body mass index, kg/m <sup>2</sup>						.853
< 25	189	1.33	183	1.36	0.96 (0.78 to 1.17)	
≥ 25	303	0.93	303	1.00	0.93 (0.79 to 1.09)	
Regional solar radiation, langleys						.218
≤ 375	260	1.03	236	1.01	1.02 (0.86 to 1.22)	
> 375	234	1.07	250	1.22	0.87 (0.73 to 1.04)	
History of nonmelanoma skin cancer						.217
Yes	132	5.52	109	5.03	1.09 (0.84 to 1.40)	
No	362	0.81	377	0.90	0.90 (0.78 to 1.04)	
Smoking status						.678
Never	249	1.08	248	1.14	0.93 (0.78 to 1.11)	
Past	191	1.03	195	1.14	0.92 (0.75 to 1.13)	
Current	44	0.91	35	0.76	1.14 (0.73 to 1.78)	
NSAID use at screening						.967
Yes	170	1.09	173	1.16	0.94 (0.76 to 1.16)	
No	324	1.03	313	1.08	0.95 (0.81 to 1.11)	

\*Two-sided Wald static *P* values are from Cox proportional hazards models. HR = hazard ratio; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug.

**Supplementary Table 2.** Pre-specified subgroup analysis of the effect of estrogen alone (E-alone) on nonmelanoma skin cancer, stratified by characteristics at baseline\*

Subgroup	E-Along		Placebo		HR (95% CI)	P
	No. of events	Annualized %	No. of events	Annualized %		
Overall	406	1.12	414	1.11	1.03 (0.89 to 1.18)	
Age, y						.314
50–59	69	0.58	73	0.60	0.97 (0.70 to 1.35)	
60–69	181	1.12	202	1.22	0.94 (0.77 to 1.15)	
70–79	156	1.89	139	1.65	1.18 (0.94 to 1.48)	
Body mass index, kg/m <sup>2</sup>						.236
< 25	114	1.51	96	1.28	1.18 (0.90 to 1.55)	
≥ 25	291	1.02	316	1.07	0.97 (0.83 to 1.14)	
Regional solar radiation, langleys						.912
≤ 375	191	1.08	197	1.09	1.03 (0.85 to 1.26)	
> 375	215	1.16	217	1.14	1.02 (0.84 to 1.23)	
History of nonmelanoma skin cancer						.161
Yes	76	5.13	101	6.07	0.85 (0.63 to 1.14)	
No	330	0.95	313	0.88	1.08 (0.92 to 1.25)	
Smoking status						.512
Never	204	1.09	215	1.15	0.96 (0.79 to 1.16)	
Past	172	1.27	165	1.15	1.12 (0.91 to 1.39)	
Current	27	0.74	32	0.83	0.90 (0.54 to 1.50)	
NSAID use at screening						.172
Yes	153	1.20	178	1.29	0.91 (0.74 to 1.13)	
No	253	1.07	236	0.98	1.11 (0.93 to 1.33)	

\*Two-sided Wald static *P* values are from Cox proportional hazards models. HR = hazard ratio; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug.

**Supplementary Table 3.** Pre-specified subgroup analysis of the effect of any hormone therapy (HT) on melanoma, stratified by characteristics at baseline\*

Subgroup	Combined HT		Placebo		HR (95% CI)	P
	No. of events	Annualized %	No. of events	Annualized %		
Overall	46	0.05	49	0.06	0.92 (0.61 to 1.37)	
Age, y						.339
50–59	12	0.04	16	0.06	0.73 (0.35 to 1.55)	
60–69	22	0.06	16	0.04	1.34 (0.70 to 2.55)	
70–79	12	0.06	17	0.09	0.70 (0.34 to 1.47)	
Body mass index, kg/m <sup>2</sup>						.867
< 25	12	0.05	12	0.06	0.99 (0.45 to 2.21)	
≥ 25	34	0.05	36	0.06	0.92 (0.57 to 1.47)	
Regional solar radiation, langleys						.637
≤ 375	26	0.06	25	0.06	1.00 (0.58 to 1.73)	
> 375	20	0.05	24	0.06	0.82 (0.46 to 1.49)	
History of nonmelanoma skin cancer						.922
Yes	7	0.15	7	0.15	0.96 (0.33 to 2.75)	
No	39	0.05	42	0.05	0.91 (0.59 to 1.40)	
Smoking status						.341
Never	26	0.06	25	0.06	1.01 (0.59 to 1.76)	
Past	19	0.06	19	0.06	0.97 (0.51 to 1.83)	
Current	1	0.01	5	0.06	0.19 (0.02 to 1.66)	
NSAID use at screening						.747
Yes	19	0.06	22	0.08	0.85 (0.46 to 1.57)	
No	27	0.05	27	0.05	0.97 (0.57 to 1.66)	

\*Two-sided Wald static *P* values are from Cox proportional hazards models. HR = hazard ratio; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug.